LYVE1 and neoplasm: Among these, HuR CRISPR-modified MDA-MB-231 tumor-bearing mice treated with DTX/omLip-HAR demonstrated the most significant reduction in 18F-FDG retention, resulting in a tumor size reduction to 26.57 ± 4.90% of the original volume at the end of the 14-day treatment (Fig. 8B).